Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 1
2014 2
2016 1
2018 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient population.
Pandya AG, Mahmoud BH, Huggins RH, Ganesan AK, Silverberg NB, Munavalli G, Weiss E, Zubair R, Lal K, Jensen JD, Skelsey MK, Ezra N, Siperstein R, Noell C, Grekin SK, Hamzavi IH. Pandya AG, et al. Among authors: grekin sk. J Am Acad Dermatol. 2025 Aug;93(2):378-386. doi: 10.1016/j.jaad.2025.03.066. Epub 2025 Mar 28. J Am Acad Dermatol. 2025. PMID: 40158537 Free article.
Effecting skin renewal: a multifaceted approach.
Widgerow AD, Grekin SK. Widgerow AD, et al. Among authors: grekin sk. J Cosmet Dermatol. 2011 Jun;10(2):126-30. doi: 10.1111/j.1473-2165.2011.00555.x. J Cosmet Dermatol. 2011. PMID: 21649818
Frostbite on the hand of a homeless man.
Yousif J, Saitta P, Grekin SK. Yousif J, et al. Among authors: grekin sk. Cutis. 2014 Jul;94(1):E5-6. Cutis. 2014. PMID: 25101353 No abstract available.
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G. Draelos ZD, et al. Among authors: grekin sk. J Am Acad Dermatol. 2018 Jun;78(6):1156-1163. doi: 10.1016/j.jaad.2018.01.027. Epub 2018 Jan 31. J Am Acad Dermatol. 2018. PMID: 29409914 Free article. Clinical Trial.
12 results